(S)-4-(oxiran-2-ylmethoxy)-1H-indazole | 340784-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (S)-4-(oxiran-2-ylmethoxy)-1H-indazole
• 英文别名: (S)-3-(Indazol-4-yloxy)-1,2-Epoxypropane；4-[[(2S)-oxiran-2-yl]methoxy]-1H-indazole
• CAS: 340784-27-2
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: GGHVECOXMJTFAC-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基吲唑 、 (S)-(+)- 间硝基苯磺酸缩水甘油酯 在 potassium carbonate 作用下， 以 乙酸乙酯 、 丙酮 为溶剂， 生成 (S)-4-(oxiran-2-ylmethoxy)-1H-indazole
  参考文献：
  名称：

  Indazolyloxy propanolamines for improving livestock production

  摘要：

  本申请公开了一种由结构式（I）表示的化合物，其中环A，环B和环C独立地被取代或未取代。R1和R2独立地是C1-C4直链或支链烷基。还公开了一种提高从家畜动物获得的肉类数量和质量的方法。该方法包括向动物施加一种或多种由结构式（I）表示的化合物的有效量。

  公开号：

  US06534504B1

文献信息

• Adrenergic receptor modulating compounds and methods of using the same
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US11173144B2

  公开（公告）日：2021-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了肾上腺素能受体调节化合物及其使用方法。还提供了治疗与肾上腺素能受体相关的疾病或病症的方法，包括施用治疗有效量的主体化合物。本公开的各个方面包括一种调节细胞中炎症通路的方法，如细胞中 TNF-α 的产生。该方法可包括使细胞与β1选择性肾上腺素能受体调节化合物接触，以选择性地激活细胞中的cAMP通路而不是β-arrestin通路。本发明还提供了包括上述化合物的药物组合物和试剂盒。
• ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20200237724A1

  公开（公告）日：2020-07-30

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.
• US6534504B1
  申请人：——

  公开号：US6534504B1

  公开（公告）日：2003-03-18
• [EN] INDAZOLYLOXY PROPANOLAMINES FOR IMPROVING LIVESTOCK PRODUCTION<br/>[FR] PROPANOLAMINES INDAZOLYLOXY DESTINES A AMELIORER LA PRODUCTIVITE DU BETAIL
  申请人：LILLY CO ELI

  公开号：WO2001036390A1

  公开（公告）日：2001-05-25

  Disclosed is compound represented by Structural Formula (I), wherein Ring A, Ring B and Ring C are independently substituted or unsubstituted. R1 and R2 are independently a C1-C4 straight chained or branched alkyl group. Also disclosed is a method of increasing the quantity and improving quality of meat obtained from a livestock animal. The method comprises administering to the animal an effective amount of one or more compounds represented by Structural Formula (I).
• [EN] TREATING WASTING SYNDROMES WITH ARYLOXY PROPANOLAMINES<br/>[FR] TRAITEMENT DES SYNDROMES CACHECTIQUES AU MOYEN DE PROPANOLAMINES ARYLOXY
  申请人：LILLY CO ELI

  公开号：WO2001035947A2

  公开（公告）日：2001-05-25

  Disclosed is a method of treating a subject with a Wasting Syndrome. The method comprising the step of administering to the subject an effective amount of a compound represented by Structural Formula (I), Ar is a substituted or unsubstituted aryl group. Ar is preferably a monocyclic heteroaryl group or a fused polycyclic heteroaryl group. Ring A has zero, one or more additional substituents. R1 and R2 are independently -H or a C1-C4 alkyl group. W is -CH2-, -CH2CH2- or -CH2CH2CH2-. R3 is a substituted or unsubstituted phenyl or pyridyl group.